



## United States Passet and Trademark Office



DATE MAILED: 01/29/2002

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/900,647	07/07/2001	Dale R. Lovercheck	ANAL-VIT	6584
75	90 01/29/2002			
Dale R. Lovercheck, Esquire			EXAMINER	
92 Patricia Place Media, PA 19063			HUI, SAN MING R	
			ART UNIT	PAPER NUMBER
			1617	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application N .	Applicant(s)
	09/900,647	LOVERCHECK, DALE R.
Office Action Summary	Examiner	Art Unit
	San-ming Hui	1617
The MAILING DATE f this communication ap Period for Reply	pears n the cover sheet with the d	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a rep - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailir earned patent term adjustment. See 37 CFR 1.704(b).  Status	136(a). In no event, however, may a reply be tirely within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	mely filed ys will be considered timely. Ithe mailing date of this communication. D (35 U.S.C. § 133).
1) Responsive to communication(s) filed on		
_	his action is non-final.	
3) Since this application is in condition for allow closed in accordance with the practice under		
Disposition of Claims	•	
4)⊠ Claim(s) <u>1-20</u> is/are pending in the applicatio	n.	
4a) Of the above claim(s) is/are withdra		
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		The second section of the section of the second section of the section of the second section of the secti
7) Claim(s) is/are objected to.		
8) Claim(s) 1-20 are subject to restriction and/or	election requirement.	
Application Papers	·	
9) The specification is objected to by the Examine	er.	
10) The drawing(s) filed on is/are: a) □ acce	epted or b) objected to by the Exa	miner.
Applicant may not request that any objection to the	ne drawing(s) be held in abeyance. S	ee 37 CFR 1.85(a).
11)☐ The proposed drawing correction filed on	_ is: a)□ approved b)□ disappro	oved by the Examiner.
If approved, corrected drawings are required in re	eply to this Office action.	
12) The oath or declaration is objected to by the Ex	xaminer.	
Priority under 35 U.S.C. 壯 119 and 120	•	
13) Acknowledgment is made of a claim for foreig	n priority under 35 U.S.C. § 119(a	)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
<ol> <li>Certified copies of the priority document</li> </ol>	ts have been received.	
2. Certified copies of the priority documen	ts have been received in Applicati	on No
<ul> <li>3. Copies of the certified copies of the price</li> <li>application from the International But</li> <li>See the attached detailed Office action for a list</li> </ul>	ureau (PCT Rule 17.2(a)).	_
14)⊠ Acknowledgment is made of a claim for domest	·	
a)  The translation of the foreign language pro	ovisional application has been rec	eived.
ttachment(s)		
Notice of References Cited (PTO-892)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	/ (PTO-413) Paper No(s) Patent Application (PTO-152)
atent and Trademark Office 326 (Rev. 04-01) Office A	ction Summary	Part of Paper No. 2

Art Unit: 1617

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-15, drawn to a system comprising an indicated discomfort reliever and an indicated nutritional supplement, classified in class 514, subclass 458, 474, 52, 276, 251, 725, 629, 277, 165, and 348; and class 424, subclass 400+.
- II. Claims 16-20, drawn to a method of providing discomfort reliever and nutritional supplement, classified in class 514, subclass 458, 474, 52, 276, 251, 725, 629, 277, 165, and 348.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different method of using that product such as anti-arthritic method.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Art Unit: 1617

## Election of Species

Claims 1-20 are generic to a plurality of disclosed patentably distinct species comprising agents of indicated discomfort reliever and indicated nutritional supplement.

Some of the species including, for example:

If the compound is Vitamin A, it is classified in class 514, subclass 725; if the compound is vitamin B<sub>12</sub>, it is classified in class 514, subclass 52; if the compound is vitamin B<sub>2</sub>, it is classified in class 514, subclass 251; if the compound is vitamin B<sub>1</sub>, it is classified in class 514, subclass 276; if the compound is vitamin B<sub>6</sub>, it is classified in class 514, subclass 348; if the compound is vitamin C, it is classified in class 514, subclass 474; if the compound is vitamin E, it is classified in class 514, subclass 458; if the compound is acetaminophen, it is classified in class 514, subclass 629; if the compound is ibuprofen, it is classified in class 514, subclass 277; if the compound is aspirin, it is classified in class 514, subclass 165.

Due to the structural dissimilarities of active compounds encompassed by the claims and their corresponding diversity in classification, the search for all species presents an undue burden on the office.

Applicant is required under 35 U.S.C. 121 to elect a <u>single disclosed</u>

<u>combination</u> of a) the discomfort reliever compound(s) <u>and</u> b) nutritional supplement compound(s), even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the

Art Unit: 1617

case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Because the above restriction/election requirement is complex, a telephone call to applicant's agent to request an oral election was not made. See M.P.E.P. Sec. 812.01.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming. Hui whose telephone number is (703) 305-1002. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Minna Moezie, J.D., can be reached on (703) 308-4612. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Art Unit: 1617

San-ming Hui January 28, 2002

MINNA MOEZIE, J.D. SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600